Cephalon beats economic downturn and raises guidance
This article was originally published in Scrip
Executive Summary
Cephalonhas increased its full-year sales and earnings guidance following record sales during the third quarter. Sales rose by 14% to $489.7 million as Cephalon's central nervous system franchise grew robustly, offsetting the declines of Actiq (fentanyl citrate).